Matches in Nanopublications for { ?s ?p "Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML). The main targets of Dasatinib, are BCRABL, SRC, Ephrins and GFR."@en ?g. }
Showing items 1 to 1 of
1
with 100 items per page.